Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Interleukin-17 inhibition in psoriatic arthritis

Psoriatic arthritis1 has struggled behind rheumatoid arthritis in terms of basic science, treatment, and national priorities. The disease is slightly less common than is rheumatoid arthritis, and the original series from Leeds, UK, suggested that psoriatic arthritis had a fairly benign outcome.2 More recently, it has become apparent that psoriatic arthritis can have an equivalently devastating effect on patient function and quality of life.3 However, important differences remain. Psoriatic arthritis is a heterogeneous disease with several musculoskeletal manifestations, and prominent extra-articular manifestations, such as psoriasis.